• Accueil >
  • Publications >
  • Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model

Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model

1 nov. 2018British Journal of Haematology

DOI : 10.1111/bjh.15009

Auteurs

Yushi Qiu, Zhimin Li, Frederic Pouzoulet, Prakash Vishnu, John A. Copland, Keith L. Knutson, Carole Soussain, Han W. Tun

Membres

FREDERIC POUZOULET

Ingénieur de recherche